Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with marked inter-individual heterogeneity in trajectories and outcomes. Despite antifibrotic therapies, reliable risk stratification in routine practice remains suboptimal. OPEN-IPF is a multicentre retrospective observational cohort study designed to build a harmonised real-world dataset across Italian IPF referral centres to enable the development and external validation of machine-learning (ML) models predicting clinically relevant outcomes.
OPEN-IPF addresses the current limitation of AI/ML research in IPF-namely, the lack of large multicentre real-world datasets with harmonised variables and robust external validation. The study will retrospectively include adult patients with IPF followed in routine practice in participating Italian referral centres from 1 January 2015 to 31 December 2025 (data lock). No study-specific procedures will be performed. De-identified/pseudonymised data will be collected using a common data model, including demographics, smoking history, comorbidities, pulmonary function (FVC, DLCO), oxygen requirement, 6-minute walk test (where available), antifibrotic treatment exposure, HRCT features routinely reported, basic laboratory parameters, and clinical outcomes. The primary modelling targets are disease progression, acute exacerbations of IPF (AE-IPF), and real-world response to antifibrotic treatment. Model development will be performed using multicentre data with explicit external validation across centres
Study Type
OBSERVATIONAL
Enrollment
1,000
Disease progression (guideline-based functional/composite criteria)
Disease progression defined using guideline-based criteria derived from routinely collected clinical data (e.g., decline in lung function and/or composite progression definitions as per the shared operational document).
Time frame: From baseline (index date) up to 12 months and up to end of available follow-up (maximum: 31 December 2025)
Acute exacerbation of IPF (AE-IPF)
Occurrence of AE-IPF during follow-up, adjudicated from routine clinical documentation using standardised operational definitions shared across centres.
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Real-world response to antifibrotic therapy
Treatment response assessed in routine clinical practice using longitudinal clinical/functional data and treatment exposure information (type, start, discontinuation)
Time frame: From treatment initiation (or baseline if already treated) up to 12 months and end of follow-up (maximum: 31 December 2025)
Overall survival
Time from baseline to death from any cause.
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Transplant-free survival
Time from baseline to lung transplantation or death.
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
Time to first progression or AE-IPF event
Time from baseline to first occurrence of disease progression or AE-IPF.
Time frame: From baseline to end of follow-up (maximum: 31 December 2025)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.